Preoperative neutrophil–to–lymphocyte ratio after chemoradiotherapy for esophageal squamous cell carcinoma associates with postoperative pulmonary complications following radical esophagectomy

Table 3 Associations of clinicopathological parameters with NLR and PLR in 111 patients with stage III esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy followed by esophagectomy

Parameters		NLR			PLR
		< 3	≥ 3	P-value	< 140	≥ 140	P-value
Age, years	< 52	20	31	0.66	12	39	0.09
	≥ 52	26	34		23	37
Primary tumor location	Upper/Middle	31	44	0.97	23	52	0.78
	Lower	15	21		12	24
Primary tumor location	Upper	11	15	0.92	6	20	0.29
	Middle/Lower	35	50		29	56
Clinical T classification	T1/2/3	22	28	0.62	17	33	0.61
	T4	24	37		18	43
Clinical N classification	N0/1	23	28	0.47	18	33	0.43
	N2/3	23	37		17	43
Clinical 7th AJCC stage	IIIA/IIIB	18	23	0.69	15	26	0.38
	IIIC	28	42		20	50
Histological grading	Grade 1/2	35	51	0.77	27	59	0.95
	Grade 3	11	14		8	17
Pathological CR	Absent	28	45	0.36	25	48	0.39
	Present	18	20		10	28
Duration (end of CRT to lab data) (days)		72.6	73.4	0.54	67.4	67.8	0.87
Blood Loss (ml)		273	259	0.50	301	248	0.36
Surgery Time (hrs)		9.82	9.89	0.71	10	9.9	0.79
Pathological T classification	CR	20	23	0.17	10	33	0.07
	1	9	4		9	4
	2	6	6		6	6
	3	7	20		6	21
	4	4	12		4	12
Pathological N classification	0	35	44	0.35	27	52	0.12
	1	9	18		5	22
	2	0	2		1	1
	3	2	0		2	0
Pathological Stage	CR	18	20	0.35	10	28	0.35
	1	5	2		5	2
	2	15	19		13	21
	3	8	22		7	23
	4	0	1		0	1

AJCC American Joint Committee on Cancer, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, CR complete response, CRT chemoradiotherapy

ISSN: 2047-0525